Barclays PLC Cogent Biosciences, Inc. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 78,143 shares of COGT stock, worth $851,758. This represents 0.0% of its overall portfolio holdings.

Number of Shares

78,143

Previous 107,653 27.41%

Holding current value

$851,758

Previous $724,000 8.84%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$6.01 - $9.04 $177,355 - $266,770	-29,510 Reduced 27.41%	78,143 $660,000
Q1 2024 May 15, 2024	SELL	$4.38 - $9.02 $532,397 - $1.1 Million	-121,552 Reduced 53.03%	107,653 $724,000
Q4 2023 Feb 15, 2024	BUY	$4.06 - $10.08 $480,269 - $1.19 Million	118,293 Added 106.65%	229,205 $1.35 Million
Q3 2023 Nov 07, 2023	SELL	$9.69 - $13.34 $14,350 - $19,756	-1,481 Reduced 1.32%	110,912 $1.08 Million
Q2 2023 Aug 03, 2023	BUY	$9.85 - $13.24 $45,260 - $60,837	4,595 Added 4.26%	112,393 $1.33 Million
Q1 2023 May 04, 2023	SELL	$10.04 - $15.5 $719,807 - $1.11 Million	-71,694 Reduced 39.94%	107,798 $1.16 Million
Q4 2022 Feb 13, 2023	BUY	$10.65 - $14.84 $332,663 - $463,542	31,236 Added 21.07%	179,492 $2.08 Million
Q3 2022 Nov 03, 2022	BUY	$9.39 - $16.99 $1.37 Million - $2.47 Million	145,473 Added 5227.2%	148,256 $2.21 Million
Q2 2022 Aug 12, 2022	SELL	$3.92 - $9.73 $122,927 - $305,123	-31,359 Reduced 91.85%	2,783 $25,000
Q1 2022 May 16, 2022	BUY	$5.31 - $8.7 $181,294 - $297,035	34,142 New	34,142 $257,000

Others Institutions Holding COGT

# of Institutions

159

Shares Held

114M

Call Options Held

104K

Put Options Held

163K

View Full List

About Cogent Biosciences, Inc.

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $717M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

More about COGT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account